Paul Peter Tak
Paul Peter Tak is a business leader, academic, entrepreneur and clinician who has over 30 years’ experience in medicine as a prominent expert in Immunology, Internal Medicine, and Rheumatology. Paul Peter is currently the President, CEO, and Board Director of Candel Therapeutics, the Co-Founder and Board Director of Sitryx Therapeutics, and Board Director of Levicept and Citryll.
Alongside his industry career, Paul Peter has dedicated much of his life to academia and advancing our understanding in medicine. He has served as Professor of Medicine at the University of Amsterdam and holds numerous honours for his service to medicine, with a special focus on Immunology and Rheumatology.
Congratulations @StavrosZanos .
After the first scientific publication proposing the idea to stimulate the cholinergic anti-inflammatory pathway/inflammatory reflex as a new therapeutic strategy for rheumatoid arthritis (RA) (Nat Rev Rheumatol, 2009 vol. 5(4) pp. 229-32) and the…
New paper out! Selective VNS using temporal interference controls spatial & temporal activation of organ-specific vagal fibers.
Terrific work by Weigo Song (http://TNPlab.org), Nicolo Rossetti & Philipp Schepel (imec).
https://www.nature.com/articles/s41467-025-59595-4
Today we announced our Q1 2025 financial results and provided corporate updates on our development programs.
Full details: https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-reports-first-quarter-2025-financial-results
$CADL
Candel Therapeutics continued strong momentum of compelling clinical evidence, reinforcing our promising pipeline of pan solid tumor immunotherapies. Our primary focus for 2025 remains on working toward CAN-2409’s BLA submission for prostate cancer, which we believe represents a…
